Active substance
Results for the substance ertugliflozin sitagliptin
2 results
About this active substance
The combination of ertugliflozin and sitagliptin is used for the treatment of type 2 diabetes mellitus, particularly in patients who cannot control their blood sugar levels through diet and exercise alone. This combination combines two different mechanisms to lower blood glucose levels.
- Ertugliflozin is an SGLT2 (sodium-glucose co-transporter 2) inhibitor that works by increasing glucose excretion through the urine, thereby lowering blood sugar levels. It may also contribute to weight loss and blood pressure reduction.
- Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that increases the levels of active incretins. These incretins stimulate insulin secretion and reduce glucose production in the liver, depending on blood sugar levels.
This combination is taken orally, usually once daily, with or without food. It is indicated for adult patients with type 2 diabetes, either as combination therapy or in conjunction with other antidiabetic medications.
Common side effects include genital infections (especially in women), urinary tract infections, nausea, diarrhea, headache, and, in rare cases, diabetic ketoacidosis. Sitagliptin may rarely cause severe allergic reactions or pancreatitis.
Patients should strictly follow their doctor’s instructions, regularly monitor their blood sugar levels, and maintain adequate hydration. The combination is not recommended for patients with severe renal impairment, liver failure, or a high risk of diabetic ketoacidosis.
- Ertugliflozin is an SGLT2 (sodium-glucose co-transporter 2) inhibitor that works by increasing glucose excretion through the urine, thereby lowering blood sugar levels. It may also contribute to weight loss and blood pressure reduction.
- Sitagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that increases the levels of active incretins. These incretins stimulate insulin secretion and reduce glucose production in the liver, depending on blood sugar levels.
This combination is taken orally, usually once daily, with or without food. It is indicated for adult patients with type 2 diabetes, either as combination therapy or in conjunction with other antidiabetic medications.
Common side effects include genital infections (especially in women), urinary tract infections, nausea, diarrhea, headache, and, in rare cases, diabetic ketoacidosis. Sitagliptin may rarely cause severe allergic reactions or pancreatitis.
Patients should strictly follow their doctor’s instructions, regularly monitor their blood sugar levels, and maintain adequate hydration. The combination is not recommended for patients with severe renal impairment, liver failure, or a high risk of diabetic ketoacidosis.